Octreotide implant - Endo Pharmaceuticals Solutions

Drug Profile

Octreotide implant - Endo Pharmaceuticals Solutions

Alternative Names: VP 003

Latest Information Update: 23 Mar 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Valera Pharmaceuticals
  • Developer Endo Pharmaceuticals Solutions
  • Class Antineoplastics; Antisecretories; Cyclic peptides; Indoles; Somatostatins
  • Mechanism of Action Growth hormone releasing factor antagonists; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Acromegaly; Malignant carcinoid syndrome

Most Recent Events

  • 07 Aug 2013 Biomarkers information updated
  • 11 Nov 2011 Discontinued - Phase-III for Acromegaly in Czech Republic (SC)
  • 11 Nov 2011 Discontinued - Phase-III for Acromegaly in Germany (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top